Seeing further.

THAT’S OUR TARGET

We’re advancing our RNA-based treatments so patients with cancers and rare diseases can enjoy the moments that matter.

Learn More

News

BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference

RESEARCH TRIANGLE PARK, N.C. and EXTON, Pa., June 13, 2018 (GLOBE NEWSWIRE) -- BioCryst… Read more 

Idera Pharmaceuticals Reports Results from Phase 2 Trial of IMO-8400 in Dermatomyositis

Clinical trial did not meet primary endpoint of statistically significant reduction of CDASI for… Read more 

Idera Pharmaceuticals Presents Clinical Data from the ILLUMINATE-204 Trial of the Combination of tilsotolimod and ipilimumab for Anti-PD-1 Refractory Metastatic Melanoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

- Data from Ongoing Phase 2 Study to be Presented at 1:15 PM CT at the  2018 American Society of… Read more 

Learn More

Events

Idera Pharmaceuticals, Inc. Events

Idera Pharmaceuticals, Inc. Events… Read more 

Learn More